Medtronic divulges Type 2 diabetes outcomes data for MiniMed

Medtronic ($MDT) has released the latest study results from its MiniMed insulin pump/continuous glucose monitor. The 12-month data show that after crossing over to MiniMed from 6 months of multiple daily insulin (MDI) injections, A1C reduction improved from 0.4% to 0.8% while using 19% less insulin. The company said this is the largest randomized, controlled trial to compare efficacy and safety of insulin pumps versus multiple daily insulin injections in poorly controlled Type 2 diabetics. "We found that participants who switched from MDI to insulin pumps were able to achieve these same results by the 12-month mark," said Dr. Ronnie Aronson, the lead author of the continuation study phase and executive director at LMC Diabetes & Endocrinology in Canada in a statement. "Given that many patients with type 2 diabetes have difficulty achieving glycemic control, these additional data demonstrate that insulin pumps provide a significant advantage over MDI with a safe and consistent effect." More

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.